Neumora Therapeutics, Inc. (NMRA)
0.487
-0.08
(-13.96%)
USD |
NASDAQ |
Nov 05, 16:00
0.473
-0.01
(-2.87%)
After-Hours: 20:00
Neumora Therapeutics SG&A Expense (TTM) : 53.16M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.16M |
| March 31, 2026 | 55.57M |
| December 31, 2025 | 60.09M |
| September 30, 2025 | 63.29M |
| June 30, 2025 | 67.13M |
| March 31, 2025 | 67.00M |
| December 31, 2024 | 62.54M |
| September 30, 2024 | 56.76M |
| June 30, 2024 | 56.01M |
| March 31, 2024 | 50.11M |
| Date | Value |
|---|---|
| December 31, 2023 | 45.48M |
| September 30, 2023 | 41.43M |
| June 30, 2023 | 34.22M |
| March 31, 2023 | 32.72M |
| December 31, 2022 | 31.12M |
| September 30, 2022 | 27.87M |
| June 30, 2022 | 19.82M |
| March 31, 2022 | 12.03M |
| March 31, 2021 | 3.942M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| EyePoint, Inc. | 55.41M |
| Context Therapeutics, Inc. | 8.619M |
| LENZ Therapeutics, Inc. | 159.82M |
| BioAge Labs, Inc. | 28.84M |
| ANI Pharmaceuticals, Inc. | 324.76M |